Abbott’s Ionicrf Generator adds option for Americans living with chronic pain

Radiofrequency ablation deactivates nerves associated with pain for up to one year

IonicRF Generator

Abbott announced the IonicRF Generator’s launch – a new device recently cleared by the US Food and Drug Administration to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system. The IonicRF Generator is a radiofrequency ablation device that uses heat to target specific nerves and block pain signals from reaching the brain.

The new device is the first Abbott-developed radiofrequency ablation device and is currently approved in the United States and Europe. “Every patient is different and the source of their pain is unique, making it extremely important to have multiple options available, so treatment can be tailored to individual circumstances,” said Jason E Pope, managing director, Evolve Restorative Center, Santa Rosa, Calif. “Abbott’s IonicRF is an advanced device platform that targets specific nerves to block pain signals from reaching the brain. One of the most promising aspects of the therapy is its effectiveness in targeting pain in several discrete areas of the body.”

According to Abbott, radiofrequency ablation uses an electric current to heat a small nerve tissue area to stop it from sending pain signals. Studies have shown that pain relief following a single radiofrequency ablation treatment can last from six to 12 months. Low back pain is among the most common medical complaints worldwide—and facet joint syndrome, often treated by radiofrequency ablation therapy, is estimated to account for 15% of these complaints. Radiofrequency ablation has been used to treat pain, such as low back pain and Sacroiliac joint (buttocks) pain, that failed to resolve with conservative treatments, such as physical therapy, injections, or medication.

“Most people who are candidates for radiofrequency ablation have tried other therapies, such as medications and injections, with limited success. As a result, they are now seeking an alternative solution that does not require surgery or the use of opioid medication,” said Keith Boettiger, vice president, Neuromodulation, Abbott. “We are proud to be able to provide the first Abbott-designed radiofrequency ablation device engineered to deliver safe and effective pain management.* This is another example of our focus on widening the breadth of our neuromodulation portfolio and keeping patients central to everything we do at Abbott.”


Please enter your comment!
Please enter your name here